The two instruments are intended for regulatory tests and for internal education and training of marketing and sales staff at the VibroSense Chinese partner UMCARE.

The work on translation of training and product documents will begin in the autumn. During the next year, internal education and training of marketing and sales personnel at UMCARE will begin.

"The collaboration with UMCARE is going well and developing very satisfactorily. It feels really exciting that we have the first two instruments in place in China. This enables us to start the planned training of UMCARE's staff as part of our preparatory work for the upcoming launch of " Diabetic Foot Screening" , says Hans Wallin, CEO of VibroSense Dynamics AB.

About diabetes in China
According to a 2020 estimate by the American Diabetes Association (ADA), there are approximately 130 million patients with diabetes in China, making the country the largest market for diabetes care in the world. There are about 36,000 hospitals, of which 24,000 are private and 12,000 are public. The cost of diabetes care is estimated at the equivalent of SEK 800 billion per year.

Contact
Hans Wallin, CEO VibroSense Dynamics AB
Tel: +46 40 88 026
Email: info@vibrosense.com
www.vibrosense.se

"The new Gold Standard for reliable
detection of nerve damage"

About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (publ) develops and sells medical technology products and services for diagnostic support for nerve damage in the hands and feet. The method involves measuring and quantifying the ability to feel vibrations at several frequencies. The company's customers are diabetes clinics, occupational health care, hospitals, health centers and researchers.

Our vision is that the company's products should be a standard instrument in all neurological examinations to detect early signs of changes in sensation so that patients and their caregivers can implement preventive measures that prevent, reduce or delay the onset of nerve damage in the hands and feet.